SCHEMBL988007

SCHEMBL988007

C[n+]1ccn(Cn2cc[n+](C)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 1/20 0.52
APAF1 O14727 1/20 0.52
NPC1 O15118 1/20 0.52
PLA2G1B P04054 1/20 0.52
HSP90AA1 P07900 1/20 0.52
MAPT P10636 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
RAB9A P51151 1/20 0.52
KMT2A Q03164 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
ATG4B Q9Y4P1 1/20 0.52
FDPS P14324 2/20 0.43
LMNA P02545 1/20 0.41
PON1 P27169 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4416367 0.97 SMN1; SMN2 (0.55) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Hydrochloric Acid SCHEMBL4417695 0.97 SMN1; SMN2 (0.50) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Iodide SCHEMBL4414352 0.97 SMN1; SMN2 (0.50) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL6403529 0.84
SCHEMBL15136817 0.83 SMN1; SMN2 (0.63) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
SCHEMBL34729 0.81
Water SCHEMBL17764770 0.81 SMN1; SMN2 (0.61) SMN1; SMN2MEN1APAF1NPC1PLA2G1B
Hydrogen Sulfide SCHEMBL16733052 0.79
SCHEMBL14499200 0.79
Water SCHEMBL409263 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303604-A1 METALLIC TRANS-(N-HETEROCYCLIC CARBENE)-AMINE-PLATINUM COMPLEXES AND USES THEREOF FOR TREATING CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-09-28 US disclosed
US-20180079651-A1 NOVEL METHODS FOR PRODUCING CRYSTALLINE MICROPOROUS SOLIDS WITH THE RTH TOPOLOGY AND COMPOSITIONS DERIVED FROM THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2018-03-22 US disclosed
US-9908783-B2 Methods for producing crystalline microporous solids with the RTH topology and compositions derived from the same CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2018-03-06 US disclosed
US-9873113-B2 Methods for producing crystalline microporous solids with a new CIT-7 topology and compositions derived from the same CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2018-01-23 US disclosed
US-9861968-B2 Methods for producing crystalline microporous solids with the HEU topology and compositions derived from the same CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2018-01-09 US disclosed
US-9782759-B2 Methods for producing crystalline microporous solids with IWV topology and compositions derived from the same CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2017-10-10 US disclosed
US-20160369354-A1 METHOD OF TARGETING MISMATCHED DNA USING d8 SQUARE PLANAR METAL COMPLEXES THE UNIVERSITY OF HONG KONG (CN) 2016-12-22 US disclosed
EP-2718394-B1 PHOSPHORESCENT METAL COMPLEX COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND RADIATION EMITTING STRUCTURAL ELEMENT OSRAM GMBH (DE) 2015-08-26 EP disclosed
US-20150202603-A1 NOVEL METHODS FOR PRODUCING CRYSTALLINE MICROPOROUS SOLIDS WITH THE HEU TOPOLOGY AND COMPOSITIONS DERIVED FROM THE SAME NATIONAL SCIENCE FOUNDATION 2015-07-23 US disclosed
US-20150203357-A1 NOVEL METHODS FOR PRODUCING CRYSTALLINE MICROPOROUS SOLIDS WITH A NEW CIT-7 TOPOLOGY AND COMPOSITIONS DERIVED FROM THE SAME CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-07-23 US disclosed
EP-2718394-A1 PHOSPHORESCENT METAL COMPLEX COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND RADIATION EMITTING STRUCTURAL ELEMENT OSRAM GmbH (DE) 2014-04-16 EP disclosed
US-20130164748-A1 Detection of nucleic acid amplification APPLIED BIOSYSTEMS LLC (US) 2013-06-27 US disclosed
US-8247574-B2 Use of PT -and PD-BIS- and tetra-carbon complexes with bridged carbon ligands in OLEDs BASF SE (DE) 2012-08-21 US disclosed
US-8247574-B2 Use of PT -and PD-BIS- and tetra-carbon complexes with bridged carbon ligands in OLEDs BASF SE (DE) 2012-08-21 US disclosed
US-8247574-B2 Use of PT -and PD-BIS- and tetra-carbon complexes with bridged carbon ligands in OLEDs BASF SE (DE) 2012-08-21 US disclosed
WO-2011000616-A1 PHOSPHORESCENT METAL COMPLEX COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND RADIATION EMITTING STRUCTURAL ELEMENT SIEMENS AKTIENGESELLSCHAFT (DE) 2011-01-06 WO disclosed
US-20090326237-A1 USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS BASF SE (DE) 2009-12-31 US disclosed
US-20090326237-A1 USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS BASF SE (DE) 2009-12-31 US disclosed
US-20090326237-A1 USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS BASF SE (DE) 2009-12-31 US disclosed
US-20070099211-A1 Detection of nucleic acid amplification APPLIED BIOSYSTEMS, LLC 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303604-A1 METALLIC TRANS-(N-HETEROCYCLIC CARBENE)-AMINE-PLATINUM COMPLEXES AND USES THEREOF FOR TREATING CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MGMT, SLC11A2 SMN1; SMN2 2061/4885MEN1 20/4885APAF1 2689/4885
US-20180079651-A1 NOVEL METHODS FOR PRODUCING CRYSTALLINE MICROPOROUS SOLIDS WITH THE RTH TOPOLOGY AND COMPOSITIONS DERIVED FROM THE SAME TREH, SIN3A, HNRNPH3 SMN1; SMN2 2376/4885MEN1 1554/4885APAF1 2933/4885
US-20150202603-A1 NOVEL METHODS FOR PRODUCING CRYSTALLINE MICROPOROUS SOLIDS WITH THE HEU TOPOLOGY AND COMPOSITIONS DERIVED FROM THE SAME HNRNPU, STOM, SPOUT1 SMN1; SMN2 3205/4885MEN1 344/4885APAF1 2151/4885
US-20090326237-A1 USE OF PT-AND PD-BIS-AND TETRA-CARBON COMPLEXES WITH BRIDGED CARBON LIGANDS IN OLEDS PDCD1, PDCD1LG2, CD274 SMN1; SMN2 4711/4885MEN1 3251/4885APAF1 3107/4885
US-20150203357-A1 NOVEL METHODS FOR PRODUCING CRYSTALLINE MICROPOROUS SOLIDS WITH A NEW CIT-7 TOPOLOGY AND COMPOSITIONS DERIVED FROM THE SAME CA7, MCM7, IPO7 SMN1; SMN2 3972/4885MEN1 398/4885APAF1 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.